中国临床药理学杂志2024，Vol.40Issue(12)：1832-1834,3.DOI:10.13699/j.cnki.1001-6821.2024.12.028
诊断生长抑素受体阳性神经内分泌肿瘤的新一代放射性试剂Copper Cu 64 dotatate
Copper Cu 64 dotatate,a new diagnostic agent for somatostatin receptor-positive neuroendocrine tumors
胥明珠 1陈超阳 2魏然 2张玄龄 2周颖3
作者信息
- 1. 北京大学第一医院药剂科,北京 100034||中国药科大学基础医学与临床药学学院,江苏南京 210009
- 2. 北京大学第一医院药剂科,北京 100034
- 3. 北京大学第一医院药剂科,北京 100034||北京大学第一医院药物临床试验机构,北京 100034
- 折叠
摘要
Abstract
On September 3,2020,the U.S.Food and Drug Administration(FDA)granted formal approval to Copper Cu 64 dotatate(commercially known as Detectnet),for its pivotal role in diagnosing somatostatin receptor(SSTR)positive neuroendocrine tumors(NETs)in adult patients.This innovative diagnostic agent,Copper Cu 64 dotatate,is a sophisticated radionuclide that selectively targets somatostatin receptors,facilitating the emission of positron(β+)radionuclides in a quantity conducive for high-resolution positron emission tomography(PET)imaging.This review delves into the intricate mechanisms of action,the dynamic pharmacokinetics,comprehensive clinical studies,and the safety profile of Copper Cu 64 dotatate,highlighting its significance in the realm of medical diagnostics.关键词
Copper Cu 64 dotatate/神经内分泌肿瘤/生长抑素受体Key words
Copper Cu 64 dotatate/neuroendocrine tumors/somatostatin receptor分类
医药卫生引用本文复制引用
胥明珠,陈超阳,魏然,张玄龄,周颖..诊断生长抑素受体阳性神经内分泌肿瘤的新一代放射性试剂Copper Cu 64 dotatate[J].中国临床药理学杂志,2024,40(12):1832-1834,3.
